DBV Technologies (NASDAQ: DBVT) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced the planned resubmission of a BLA to the United States FDA. Of course, the news excited investors, pushing the stock upward. Today, we’ll talk about:
- The coming BLA resubmission;
- what we’re seeing from DBVT stock as a result; and
- what we’ll be watching for ahead.
DBVT Heads Up On BLA Resubmission Plans
As mentioned above, DBV Technologies is having an incredibly strong start to the trading session this morning after announcing a planned Biologics License Application (BLA) resubmission.
In the release, DBVT said that it plans on resubmitting the BLA for Viaskin Peanut in the treatment of peanut-allergic children ages 4 to 11. In fact, the company said that it expects to submit this BLA in the third quarter of 2019.
In a statement, Daniel Tasse, CEO at DBVT, had the following to offer:
We appreciate the detailed feedback the FDA provided in December 2018, which has allowed us to make meaningful headway in addressing the information requests needed for a BLA resubmission. We are working diligently on our Viaskin Peanut BLA, bringing us one step closer to potentially providing an FDA-approved treatment for peanut-allergic children and their families.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to DBV Technologies, the news proved to be overwhelmingly positive. After all, the submission that will be taking place in the third quarter could be the company’s path toward regulatory approval and revenue generation from this product. So, it’s not surprising to see that excited investors are pushing the stock up in the market this morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:08), DBVT is trading at $7.66 per share after a gain of $0.61 per share or 8.65% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on DBVT. In particular, we’re interested in following the story surrounding the company’s continued work to bring Viaskin Peanut to market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!